Sample size calculation of clinical trials in geriatric medicine.
Alpha error
Beta error
RCT
Randomized clinical trial
Sample size calculation
Study power
Journal
Aging clinical and experimental research
ISSN: 1720-8319
Titre abrégé: Aging Clin Exp Res
Pays: Germany
ID NLM: 101132995
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
27
02
2020
accepted:
11
05
2020
pubmed:
27
5
2020
medline:
1
5
2021
entrez:
27
5
2020
Statut:
ppublish
Résumé
A preliminary step when planning a randomized clinical trial (RCT) is the sample size calculation. This is the determination of the optimal number of patients which ensures an adequate power to the study to detect as statistically significant a certain between-arms difference, if any, in the frequency/magnitude of a specific endpoint. The sample size calculation is performed by specific calculators requiring as input variables the expected effect size, the alpha error (α), the beta error (β) and the allocation ratio, this latter being the ratio between the number of participants allocated to the arms of a RCT. Herein, we provide a series of examples of sample size calculation in the context of superiority RCTs in elderly.
Identifiants
pubmed: 32451964
doi: 10.1007/s40520-020-01595-z
pii: 10.1007/s40520-020-01595-z
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1209-1212Références
Stel VS, Zoccali C, Dekker FW et al (2009) The randomized controlled trial. Nephron Clin Pract 113:c337–342
doi: 10.1159/000237143
Flight L, Julious SA (2016) Practical guide to sample size calculations: non-inferiority and equivalence trials. Pharm Stat 15:80–89
doi: 10.1002/pst.1716
Lesaffre E (2008) Superiority, equivalence, and non-inferiority trials. Bull NYU Hosp Jt Dis 66:150–154
pubmed: 18537788
Sackett DL, Haynes RB, Guyatt GH et al (1991) Clinical epidemiology. A basic science for clinical medicine, 2nd edn. Little, Brown and Company, Boston
Altman N, Krzywinski M (2013) Power and sample size. Nat Methods 10:1139–1140
doi: 10.1038/nmeth.2738
Mason MJ (1999) A review of procedural and statistical methods for handling attrition and missing data in clinical research measurement and evaluation. Counsel Dev 32:111–118
Hui D, Glitza I, Chisholm G et al (2013) Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trials. Cancer 119:1098–1105
doi: 10.1002/cncr.27854
McNeil JJ, Woods RL, Nelson MR et al (2018) Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med 379:1499–1508
doi: 10.1056/NEJMoa1800722
Group AI (2013) Study design of ASPirin in reducing events in the elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials 36:555–564
doi: 10.1016/j.cct.2013.09.014
Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242
doi: 10.1056/NEJMoa011795
Oliva EN, Alati C, Santini V et al (2017) Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol. 4:e127–e136. https://doi.org/10.1016/S2352-3026(17)30012-1
doi: 10.1016/S2352-3026(17)30012-1
pubmed: 28162984
Chatfield MD, Brayne CE, Matthews FE (2005) A systematic literature review of attrition between waves in longitudinal studies in the elderly shows a consistent pattern of dropout between differing studies. J Clin Epidemiol 58:13–19
doi: 10.1016/j.jclinepi.2004.05.006
Gardette V, Coley N, Toulza O et al (2007) Attrition in geriatric research: how important is it and how should it be dealt with? J Nutr Health Aging 11:265–271
pubmed: 17508106